ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
{{output}}
Clinical trials have identified ARID1A mutations as enriched among patients who respond favorably to immune checkpoint blockade (ICB) in several solid tumor types independent of microsatellite instability. We show that ARID1A loss in murine models is sufficien... ...
